Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study

This publication has 11 references indexed in Scilit:

• Impact of Naturally Occurring Variants of HCV Protease on the Binding of Different Classes of Protease Inhibitors
  Biochemistry, 2006
• Antiviral efficacy of NS3‐serine protease inhibitor BILN‐2061 in patients with chronic genotype 2 and 3 hepatitis C†‡
  Hepatology, 2005
• Combination of a Hepatitis C Virus NS3-NS4A Protease Inhibitor and Alpha Interferon Synergistically Inhibits Viral RNA Replication and Facilitates Viral RNA Clearance in Replicon Cells
  Antimicrobial Agents and Chemotherapy, 2004
• Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
  Gastroenterology, 2004
• In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
  Journal of Biological Chemistry, 2004
• Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C
  Annals of Internal Medicine, 2004
• Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003
  Hepatology, 2004
• An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
  Nature, 2003
• Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
  New England Journal of Medicine, 2002
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
  Published by Elsevier ,2001